These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 20046661)

  • 21. Evaluation of oral sugar test response for detection of equine metabolic syndrome in obese Crioulo horses.
    Cantarelli C; Dau SL; Stefanello S; Azevedo MS; De Bastiani GR; Palma HE; Brass KE; De La Côrte FD
    Domest Anim Endocrinol; 2018 Apr; 63():31-37. PubMed ID: 29287187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of nutritional therapy in the treatment of equine Cushing's syndrome and laminitis.
    Harman J; Ward M
    Altern Med Rev; 2001 Sep; 6 Suppl():S4-16. PubMed ID: 11591169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Equine Cushing's disease.
    Love S
    Br Vet J; 1993; 149(2):139-53. PubMed ID: 8485640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin dysregulation in a population of Finnhorses and associated phenotypic markers of obesity.
    Box JR; McGowan CM; Raekallio MR; Mykkänen AK; Carslake H; Karikoski NP
    J Vet Intern Med; 2020 Jul; 34(4):1599-1605. PubMed ID: 32557899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adipose tissue dysfunction in obese horses with equine metabolic syndrome.
    Reynolds A; Keen JA; Fordham T; Morgan RA
    Equine Vet J; 2019 Nov; 51(6):760-766. PubMed ID: 30866087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Age, Season, Body Condition, and Endocrine Status on Serum Free Cortisol Fraction and Insulin Concentration in Horses.
    Hart KA; Wochele DM; Norton NA; McFarlane D; Wooldridge AA; Frank N
    J Vet Intern Med; 2016; 30(2):653-63. PubMed ID: 26860336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
    Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
    Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal glucose metabolism and peripheral insulin sensitivity in equine pituitary pars intermedia dysfunction.
    Klinkhamer K; Menheere PP; van der Kolk JH
    Vet Q; 2011 Mar; 31(1):19-28. PubMed ID: 22029818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence and risk factors for recurrence of endocrinopathic laminitis in horses.
    de Laat MA; Reiche DB; Sillence MN; McGree JM
    J Vet Intern Med; 2019 May; 33(3):1473-1482. PubMed ID: 30972832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Nutritional laminitis--preventive measures for the obese horse].
    Kienzle E; Fritz J
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 2013; 41(4):257-64; quiz 265. PubMed ID: 23959622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nutrition of horses with equine pituitary pars intermedia dysfunction ("Cushing's syndrome") treated with pergolid - A field study].
    Kienzle E; Bockhorni T
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 2018 Aug; 46(4):249-256. PubMed ID: 30142655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endocrinopathic Laminitis.
    Grenager NS
    Vet Clin North Am Equine Pract; 2021 Dec; 37(3):619-638. PubMed ID: 34674908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Obesity and diet affect glucose dynamics and insulin sensitivity in Thoroughbred geldings.
    Hoffman RM; Boston RC; Stefanovski D; Kronfeld DS; Harris PA
    J Anim Sci; 2003 Sep; 81(9):2333-42. PubMed ID: 12968709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Approaches to endocrinopathic laminitis in the field: Results of a survey of veterinary practitioners in North America.
    Rumfola E; Banse HE; Atkins M; McGowan CM; Ireland JL
    J Equine Vet Sci; 2022 Mar; 110():103856. PubMed ID: 34958881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of peripheral blood neutrophil respiratory burst, phagocytosis and apoptosis in obese non-insulin dysregulated horses.
    Salinas C; Espinosa G; Morales N; Henríquez C; Morán G; Gajardo G; Uberti B
    Res Vet Sci; 2020 Oct; 132():127-132. PubMed ID: 32563928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equine laminitis--another hypothesis for pathogenesis.
    Field JR; Jeffcott LB
    Med Hypotheses; 1989 Nov; 30(3):203-10. PubMed ID: 2689849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
    Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
    Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Equine metabolic syndrome.
    Frank N
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):73-92. PubMed ID: 21392655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease.
    Orth DN; Nicholson WE
    Endocrinology; 1982 Aug; 111(2):559-63. PubMed ID: 6284484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants.
    McFarlane D; Beech J; Cribb A
    Domest Anim Endocrinol; 2006 May; 30(4):276-88. PubMed ID: 16115743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.